1. Failure After Failure. What Next in AD Drug Development?

   • P. S. Aisen

   Editorial 18 April 2019 Pages: 150 - 150

2. Tau Based Therapeutics: Alternative Approaches in the War on Alzheimer’s Disease

   • Michael Grundman

   Editorial 18 April 2019 Pages: 151 - 152

3. Is Now the Time for Combination Therapies for Alzheimer Disease?

   • J. C. Morris

   Editorial 18 April 2019 Pages: 153 - 154

4. Blood Tests for Alzheimer’s Disease and Related Disorders

   • Eric M. Reiman

   Editorial 18 April 2019 Pages: 155 - 156

5. Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force

   • Jeffrey Cummings
   • K. Blennow
   • EU/US/CTAD Task Force

   CTAD Task Force Paper 18 April 2019 Pages: 157 - 163

   

6. Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force

   • Serge Gauthier
   • J. Alam
   • EU/US/CTAD Task Force

   CTAD Task Force Paper 18 April 2019 Pages: 164 - 168

   

7. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report

   • Randall J. Bateman
   • K. Blennow
   • EU/US CTAD Task Force

   CTAD Task Force Paper 18 April 2019 Pages: 169 - 173

8. Treating Alzheimer’s Disease : Combine or Fail ?

   • Serge Bakchine

   Commentary 18 April 2019 Pages: 174 - 176

9. Opportunities for Combination Trials

   • Clive Ballard
   • A. Corbett

   Commentary 18 April 2019 Pages: 177 - 178

10. Combination Therapy for Alzheimer’s Disease — The Next Step

    • Frank Jessen

    Commentary 18 April 2019 Pages: 179 - 179

11. Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force

    • E. Siemers

    Commentary 18 April 2019 Pages: 180 - 181

12. Development of the Blood-Based Alzheimer’s Disease Liquid Biopsy

    • Harald Hampel
    • S. Lista
    • Alzheimer Precision Medicine Initiative (APMI)

    Commentary 18 April 2019 Pages: 182 - 184

13. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer’s Disease Patients in the General Population

    • O. Uspenskaya-Cadoz
    • C. Alamuri
    • C. Rubel

    Original Research 23 April 2019 Pages: 185 - 191

    

14. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer’s Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study

    • Eduardo Cumbo
    • S. Cumbo
    • D. Migliore

    Original Research 23 April 2019 Pages: 192 - 197

    

15. Advancing Alzheimer’s Disease Treatment: Lessons from CTAD 2018

    • B. Vellas
    • L. J. Bain
    • P. S. Aisen

    Review 04 April 2019 Pages: 198 - 203

16. Dietary Fat Intake and Cognitive Function among Older Populations: A Systematic Review and Meta-Analysis

    • G.-Y. Cao
    • M. Li
    • Beibei Xu

    Review 22 March 2019 Pages: 204 - 211